WOMEN IN FINANCE • April 15, 2026

Jordan Has Twenty-Three LPs in Gray, Fourteen in Red, Twenty-Two in Yellow, and Twelve in Green

Jordan sits at the desk by the window of her Palo Alto co-working space, the faint hum of the broken fountain in the courtyard filtering through the glass. It’s 9:01 p.m. on a Thursday, and the $640 monthly rent feels like a small price for a place where she doesn’t have to cry in her home office anymore. The glow from her laptop casts shadows across her face, tired but unyielding.

Her Fund II tracker dominates the screen: 71 LP names, each tagged with a color code that feels like a silent verdict on her future. Twenty-three are gray — no response in over thirty days. Fourteen are red — hard passes. Twenty-two are yellow — interested, but only at a smaller check size. Twelve are green — officially in. Jordan’s eyes flick to the printout on her desk, the LP’s exact feedback underlined in pen: “Strong Fund I selection, but wanted to see more conviction-led concentration and faster mark-ups in Fund II given current LP environment.” She’s read that sentence eleven times tonight.

Her Slack tab blinks. It’s a message from the founder of her best-performing portfolio company, a Series B SaaS with a $480 million post-money valuation. The co-founder is leaving. Jordan reads the message twice, hesitating, then closes the tab. The silence that follows feels heavier than any word she could type.

She thinks: “Fund I was about whether I could be a venture capitalist. Fund II is about whether the LP community has already decided I am not. I am thirty-eight. The decision is being made by people I cannot reach. The decision was already made on Tuesday. I am still pretending it is being made.”

What “Fund II Pressure” Actually Is — And Why It Is a Different Animal From the Fund I Raise

Fund II pressure isn’t simply a repeat of Fund I with more stress. It’s a fundamentally different experience. Fund I is the leap into the unknown, the proving ground where ambition meets possibility. Fund II is the crucible where judgment and history collide — the LPs have a dossier on you now, and every portfolio mark, every decision, every founder’s departure is scrutinized with an unforgiving gaze.

This phase tests more than your investment acumen. It tests your nervous system’s capacity to tolerate uncertainty, rejection, and the slow drip of ambiguous feedback. Unlike the Fund I raise, which often came with excitement and fresh energy, Fund II is a drawn-out season of limbo and second-guessing, where the LP universe cools and the stakes are higher.

For women solo GPs, Fund II pressure carries an added weight. It’s not just about performance; it’s about contending with the unspoken biases embedded in every LP meeting, every due diligence call, every follow-up email left unanswered.

Jordan’s fingers tremble slightly as she scrolls through her Fund II tracker, the same digital ledger she’s stared at since the last LP meeting. The color-coded names stare back at her like a barometer of her worth: twenty-three gray—silent and cold, frozen in the void of no response; fourteen red—cut loose before the first handshake; twenty-two yellow—tentative, cautious, their interest tethered to diminished check sizes; and twelve green—a fragile cluster of hope. The tracker has become a kind of oracle, its hues a language she both dreads and depends on.

Her eyes drift from the tracker to the worn printout lying beside her laptop, the LP’s exact words etched in her mind. “Strong Fund I selection, but wanted to see more conviction-led concentration and faster mark-ups in Fund II given current LP environment.” Eleven times she’s read it tonight. Each time, the sentence morphs, sometimes hardening into judgment, sometimes softening into possibility. That phrase has become a mirrored surface, reflecting not only the critique of her fund management but the undercurrent of doubt about her as a solo female GP navigating a markedly colder LP universe.

The Slack notification blinks insistently. The message is from the founder of her best-performing company—a Series B SaaS with a $480 million post-money valuation. The co-founder’s sudden departure is a seismic tremor in Jordan’s carefully built portfolio. She reads and rereads the note, the weight of uncertainty pressing down on her chest. The decision to close the tab without a reply is both a protective act and a moment of silent mourning. It’s another reminder that the Fund II crucible is not just about capital but about managing the fragility of human factors within her investments.

Jordan’s interior voice is stark and unflinching: “Fund I was about whether I could be a venture capitalist. Fund II is about whether the LP community has already decided I am not. I am thirty-eight. The decision is being made by people I cannot reach. The decision was already made on Tuesday. I am still pretending it is being made.” This thought crystallizes the unique psychological toll the sophomore GP season exerts—where performance metrics intersect with systemic bias and the gnawing isolation of solo female leadership.

The Three Mark-Driven Pressures (Faster Mark-Ups, Concentration Conviction, and the Quiet Re-Underwriting of Your Fund I Selection)

Three specific forces shape the Fund II acute institutional strain: faster mark-ups, concentration conviction, and the silent re-underwriting of your Fund I portfolio. Each one carries its own neurobiological impact, especially when the stakes are as personal as your reputation and your fund’s survival.

Faster mark-ups mean that LPs expect portfolio valuations to accelerate more quickly in Fund II than in Fund I. This demand isn’t just financial; it’s a pressure on your nervous system to perform at a pace that often outstrips market realities or company growth trajectories. The tension between what you know to be true and what others expect creates a strain that can feel like a constant low-level alarm.

Concentration conviction refers to LPs wanting to see a tighter, more focused portfolio — bets made with unwavering confidence rather than a scattershot approach. This pushes GPs to reveal a level of certainty that may not match the messy, ambiguous nature of early-stage investing, amplifying feelings of doubt and self-criticism.

Finally, the quiet re-underwriting of your Fund I selection happens behind the scenes. LPs revisit your past portfolio decisions with fresh eyes, applying new standards and often unconsciously adjusting their willingness to invest based on these judgments. For a solo female GP, this can feel like an invisible weighing scale tilted by biases she can’t name but feels acutely.

Fund II pressure is a phenomenon that defies simple comparison with the Fund I raise. The first fundraise is often imbued with the energy of novelty and possibility—there’s a story to tell, a vision to sell, and a chance to prove oneself in uncharted territory. For Jordan, Fund I was a narrative of breakthrough: assembling a $48 million fund, building a portfolio, and stepping into the venture world with a blend of ambition and hope.

But Fund II is a wholly different animal. Here, the LPs aren’t just evaluating a pitch; they’re scrutinizing a dossier of past decisions, marks, and leadership under pressure. The veil of goodwill that accompanied the first fundraise thins, replaced by a more clinical, data-driven appraisal. The LP universe has cooled, and a slower, more cautious dance unfolds. Jordan’s Fund II raise is a test of endurance, resilience, and nerve, with feedback often ambiguous—a litmus test not only of her fund’s performance but of her capacity to withstand the protracted uncertainty.

Clinically, this phase activates a unique neurobiological stress response. The sustained ambiguity triggers a chronic activation of the nervous system’s threat detection circuits. Anxiety and hypervigilance are constant companions, as Jordan must negotiate the silence of gray LPs, the firm “hard pass” reds, and the cautious “yellow” interest that feels more like a hedge than commitment. This liminal space—what Pauline Boss, PhD, calls “pre-decision limbo”—is taxing on both mind and body, exacerbating the physiological toll of the venture capital grind.

For solo women GPs, the stakes are amplified by embedded structural biases and the scarcity of supportive networks. Fund II pressure is not just a business hurdle but a crucible of identity and belonging, where every delayed response or ambiguous feedback compounds feelings of invisibility and rejection sensitivity, as Geraldine Downey, PhD’s work on rejection sensitivity illuminates. The experience is at once professional and deeply personal, shaping the contours of the sophomore GP season in ways few outside the ecosystem truly grasp.

Why the Sophomore GP Season Is Specifically Brutal for Solo Female GPs

Jordan’s experience isn’t just shaped by fund economics; it’s shaped by the subtle, systemic challenges that solo female GPs face in the venture capital ecosystem. The sophomore GP season exposes them to a unique kind of scrutiny that blends performance pressure with gendered expectations and isolation.

In a conference room on a Thursday afternoon, Jordan recalls a recent LP meeting where she was the only woman present. The partner’s eyes lingered longer on her pitch deck than her voice, and the questions she fielded felt less about her fund strategy and more about her “fit” in the male-dominated world of investing. She clenched her fists under the table, feeling the familiar surge of adrenaline and doubt — a cocktail her body knows too well.

This season is brutal because it activates old survival patterns. Solo female GPs often carry an inherited hypervigilance, a nervous system wired to scan for threat and rejection in every interaction. The stakes are not just professional; they’re existential. Every “hard pass” stings deeper when the rejection is laced with implicit bias and the pressure to prove oneself as “one of the guys” while maintaining an impeccable professional image.

At the heart of Fund II pressure lie three intertwined mark-driven forces that define LP expectations and shape the narrative arc of the sophomore raise: faster mark-ups, concentration conviction, and the quiet re-underwriting of Fund I’s portfolio selection. These forces are both financial and psychological, each exerting unique clinical and systemic stresses on the GP’s nervous system.

Faster mark-ups are a demand for accelerated validation of portfolio companies. LPs want to see portfolio valuations climb more swiftly in Fund II than they did in Fund I—a pressure that often clashes with market realities and the natural growth cycles of startups. This expectation can induce a chronic state of tension in solo GPs, who must reconcile their informed judgment with external pressure, leading to cognitive dissonance and a heightened sense of urgency.

Concentration conviction refers to LPs’ desire for a more focused, conviction-led portfolio in Fund II. This means fewer companies but larger bets—signaling confidence and decisiveness. For GPs like Jordan, this translates into a high-stakes balancing act: showing enough boldness to satisfy LPs while managing the risk inherent in putting significant capital behind fewer ventures. The neurobiological impact of this pressure includes increased stress responses, as the weight of each investment decision gains outsized significance.

The silent re-underwriting of Fund I selections is perhaps the most insidious. LPs revisit the choices made in the first fund with fresh skepticism, re-evaluating performance through the lens of their own risk tolerance and market shifts. This process can feel like a quiet interrogation of the GP’s judgment and track record, amplifying feelings of vulnerability and self-doubt. For solo female GPs, who may already grapple with heightened rejection sensitivity, this re-underwriting is a psychological battleground where past successes are questioned and future potential is under constant scrutiny.

The Specific Hazard of the “Wait Another Year of Marks” LP Response (And Why It Is Almost Always a Soft No)

At 7:18 p.m., Maya calls Jordan from her own office in San Francisco. She raised her Fund II last year and offers Jordan a dose of hard-earned honesty. “That ‘wait another year of marks’ line? It’s the polite way of saying no. It’s a soft no dressed up in hope you won’t push back too hard.”

LPs use this phrase as a shield from confrontation, a way to defer a decision while keeping the door ostensibly open. But for the GP stuck in that limbo, it’s a psychological no-man’s land. The body tenses, waiting, bracing for a verdict that never arrives. This indefinite limbo triggers what Pauline Boss, PhD, calls ambiguous loss — a grief without closure that can immobilize and exhaust.

Jordan rereads the phrase on the printout again, feeling the weight of months stretching into years, the nervous system oscillating between hope and despair. The waiting is more than frustrating; it’s a slow erosion of resilience.

The sophomore GP season holds a unique brutality for solo female GPs, layered with challenges that go beyond typical Fund II pressures. Women navigating this landscape often face amplified visibility and heightened expectations, compounded by systemic and interpersonal biases that subtly influence every interaction with potential LPs. The solo nature of their leadership adds a dimension of isolation not typically experienced by their male or co-GP counterparts.

This dynamic is deeply embodied. The constant need to prove competence in a male-dominated field triggers what Stephen Porges, PhD describes as “tonic immobility”—a state where the nervous system, overwhelmed by threat, can freeze or shut down. Jordan’s experience in her Palo Alto co-working space, away from the emotional volatility of her home office, is an act of managing this physiological response. Her body’s subtle signals of exhaustion and hypervigilance underscore the embodied cost of this season.

Moreover, the landscape of LP feedback often carries coded language that women GPs must decode while managing the emotional labor of fundraising. Phrases like “wanting to see more conviction-led concentration” or “faster mark-ups” are not just financial metrics but carry implicit gendered expectations about decisiveness, risk tolerance, and leadership style. The cumulative effect is a psychological acute institutional strain that tests not only the fund’s viability but the GP’s resilience and identity.

Clinically, this pressure can exacerbate rejection sensitivity and trigger cycles of self-questioning and internalized doubt. The solo female GP must navigate not only the external hurdles of fundraising but the internal terrain of managing rejection and ambiguous cues—often without the buffer of a co-GP or a strong support system. Understanding these dynamics is critical to supporting women in this high-stakes phase of their career.

Both/And: The Marks Will Get Better OR Worse In a Year AND The Body Cannot Hold Twelve More Months of Pre-Decision Limbo

Jordan is back at the window desk, the night darkening outside. Her fingers hover over the keyboard, the screen illuminating the same 71 LP names, the same color-coded fates. She knows the marks will either improve or deteriorate in the next twelve months — the market and portfolio companies will speak, one way or another. Yet her body resists the endless stretch of pre-decision limbo.

She remembers Maya’s words and feels the tension between hope and exhaustion, the paradox of needing to wait for clarity while feeling her nervous system fray under the strain. Her breath shortens, shoulders tighten, and the familiar ache of tonic immobility creeps in — a shutdown response to unbearable uncertainty.

This both/and is the brutal truth for many solo female GPs: the external narrative insists on patience and optimism, while the internal experience demands self-care and limits. The survival strategy that once fueled their ascent now collides with the body’s need for rest and repair.

The most fraught LP response Jordan encounters is the “wait another year of marks” refrain—a phrase that, on the surface, suggests patience but often functions as a soft no. This response is a clinical manifestation of what Pauline Boss, PhD terms “ambiguous loss,” a situation where the outcome is uncertain, and closure is deferred indefinitely. For GPs, this limbo can induce a profound sense of loss without resolution, stretching the nervous system’s capacity for tolerating uncertainty.

From a neurobiological perspective, this prolonged pre-decision limbo keeps the stress response activated, maintaining a state of hypervigilance and emotional depletion. The GP’s body and mind are caught in a feedback loop of hope and disappointment, each new quarter’s marks acting as a potential pivot point that may or may not yield progress. The emotional labor of sustaining this ambiguous state is immense, often invisible to outsiders but deeply felt by those inside the fundraising cycle.

Jordan’s experience reflects this reality: every “wait and see” is a postponement of the final verdict, prolonging the stress and eroding resilience. The impact on sleep, concentration, and emotional regulation is profound, as the body remains on alert for a decision that may never come. This cycle also deepens rejection sensitivity, as the lack of clear feedback leaves room for internal narratives of inadequacy and rejection to flourish unchecked.

Understanding the specific hazard of this LP response is essential for women GPs to develop strategies that protect their mental health and sustain their capacity to navigate the sophomore fundraise with clarity and purpose. It also highlights the need for systemic shifts in the venture capital ecosystem to address these patterns of ambiguous delay and their outsized impact on women.

Systemic Lens: Why VC’s Fund-Cycle Architecture Compounds Selection Bias Against Solo Female GPs With Every Sophomore Cycle — and What That Means for the Women Inside It

Venture capital’s fund-cycle architecture isn’t neutral. Every sophomore fundraise compounds existing selection biases against solo female GPs, layering structural obstacles onto personal challenges. The system rewards pattern recognition — but those patterns often reflect entrenched gender biases rather than objective performance.

LPs who have seen a Fund I portfolio with mixed outcomes may unconsciously downgrade a solo female GP’s Fund II prospects more harshly than a male counterpart’s. The fund cycle’s timeline, with its drawn-out decision phases and opaque feedback, creates an environment ripe for ambiguous loss and nervous system dysregulation.

Jordan’s experience is a lived example of this systemic layering. Each “no response” email, each vague piece of feedback, echoes an institutional architecture that not only evaluates her fund but also her identity as a solo female GP. This system doesn’t just shape outcomes; it shapes the very experience of fundraising for women like her.

Jordan’s body is a map of this liminal year—tight shoulders, a constricted diaphragm, and a heart racing in moments of prolonged uncertainty. The physiologic imprint of Fund II pressure is not incidental; it is central to the lived experience of solo female GPs. The tension between hope and rejection, the internalized scrutiny, and the external feedback loop of LP decisions all converge in a neurobiological storm that shapes behavior, decision-making, and emotional resilience.

The systemic architecture of venture capital’s fund cycle compounds these challenges. With each sophomore cycle, selection biases embedded in LP networks and decision-making processes disproportionately affect solo female GPs. The pattern-match bias—where LPs look for familiar profiles and track records—works against women who are often the first or only solo female GP in a room, as explored in FS04. This structural dynamic creates a feedback loop of exclusion that intensifies with every fundraise iteration.

Adrienne Rich’s insight about “the sense of actual possibilities” resonates here. The systemic biases narrow the horizon of opportunity, subtly constraining what women GPs can imagine as attainable. The neurobiological impact is profound: chronic stress responses, heightened rejection sensitivity, and the risk of tonic immobility all reflect the body’s response to systemic exclusion. Recognizing these intertwined layers—individual, relational, systemic—is critical for cultivating pathways to healing and empowerment.

For women inside this ecosystem, the intersection of clinical and systemic realities demands approaches that integrate trauma-informed care with strategic career navigation. Resources such as the Finance hub offer vital support, but addressing the root structural issues requires collective awareness and deliberate cultural change within the LP community and beyond.

What a Solo Female GP Actually Does With the Fund II Year (Three Routes: Push Through, Right-Size to a Smaller Fund II, or Pause for Cycle Three)

Jordan’s Fund II year is a crossroads. She faces three paths: push through and close the fund as planned, right-size to a smaller Fund II to align with current LP appetite, or pause and prepare for a third fundraise cycle. Each path carries emotional, financial, and physical costs.

Push through means committing to the grind despite exhaustion and uncertainty, risking burnout but preserving momentum. Right-sizing offers a pragmatic recalibration but can feel like a concession, triggering internalized doubts about capability. Pausing for cycle three allows space to rebuild and reflect but extends the limbo, taxing the nervous system further.

Jordan knows that choosing any path requires attuned self-awareness, external support, and a willingness to hold complexity. The Fund II year is not just a fundraising challenge — it’s a test of resilience, identity, and the capacity to claim space in a system designed to narrow it.

Women like Jordan find healing not in denying the cost but in acknowledging it, drawing on therapy and coaching resources that address the unique trauma of the Fund II raise — including this site’s therapy guide and executive coaching offerings designed for driven women in finance.

For more on the psychological experience of being the only woman in the room, see Only Woman in the Room. For insights on fundraising while female, this article offers valuable perspectives.

What does a solo female GP actually do with the Fund II year? Three distinct routes emerge, each with its own psychological contours and practical implications: pushing through, right-sizing to a smaller Fund II, or pausing for Cycle Three. Each path requires a nuanced appraisal of personal resilience, market realities, and systemic constraints.

Pushing through demands sustained engagement with the LP universe despite the relentless ambiguity and pressure. It calls for strong self-care strategies and often clinical support to manage the embodied stress of this season. Executive coaching and trauma-informed therapy, such as those detailed in the therapy for women in finance complete guide, become essential tools to sustain clarity and emotional regulation.

Right-sizing involves recalibrating the Fund II raise to a smaller vehicle, which may better align with prevailing LP appetite and the GP’s evolving capacity. This choice can alleviate some mark-up pressures and concentration demands but requires confronting the psychological impact of downsizing aspirations. It also opens space for strategic reorientation and rebuilding of confidence.

Pausing for Cycle Three is the most fraught option, involving an intentional hiatus to rebuild portfolio momentum, deepen relationships, and restore nervous system equilibrium. This route demands patience and acceptance of the ambiguous loss inherent in stepping back, but it can offer a crucial reset. For many women, integrating clinical insights about rejection sensitivity and tonic immobility supports moving through this pause without internalizing it as failure.

Each route is a testament to the complex interplay of personal and systemic factors shaping the sophomore GP season. Women navigating this crucible benefit from resources that address both the business realities and the embodied experience of Fund II pressure, including the insights shared in the fundraising while female series. Ultimately, healing and efficacy arise from recognizing the full cost of this season and cultivating supports that honor both the mind and body.

Medical Disclaimer

Medical Disclaimer